Ideas

Reproductive hormone protects against cardiac diseases: Relaxin-based therapy for Cardiomyopathy:  Relaxin, a protein hormone that facilitates labor and relaxes the uterine musculature, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via up-regulation of its target gene, 23/August/2018, 2.54 pm
Reproductive hormone protects against cardiac diseases: Relaxin-based therapy for Cardiomyopathy:  Relaxin, a protein hormone that facilitates labor and relaxes the uterine musculature, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via up-regulation of its target gene, 23/August/2018, 2.54 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This…

read more

A Lotus way to lengthen lifespan: The Lotus component Nucinferin-based therapy for life-span extension: Nucinferin, isolated from lotus leaf, may  increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes, 23/August/2018, 2.36 pm
A Lotus way to lengthen lifespan: The Lotus component Nucinferin-based therapy for life-span extension: Nucinferin, isolated from lotus leaf, may  increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes, 23/August/2018, 2.36 pm 960 720 Dr Boomi's Genom-2-Discovery Center

 What they say: Introduction:  A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston, USA; and Department of Pharmacology,…

read more

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: PCGF2/Mel-18 increases the expression of tumor suppressors genes, such as  HNF4α, CADM2, p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 22/August/2018, 7.48 am
Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: PCGF2/Mel-18 increases the expression of tumor suppressors genes, such as  HNF4α, CADM2, p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 22/August/2018, 7.48 am 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Combinatorial  therapy for human cancers: A pharmaceutical mixture encompassing Metformin, Berberine, Despiramine, 17-AAG, Curcumin, Calcitriol, Capsaicin, Camptothecin, Simvastatin, Salinomycin, (MBDAAGCCCSS) inhibits the expression of KAT6A and KAT6B, increases the expression of INK4a/ARF and other genes, promotes senescence, prevents cancer recurrence, and prolongs survival, via up-regulation of its target gene, 22/August/2018, 7.35  am
Combinatorial  therapy for human cancers: A pharmaceutical mixture encompassing Metformin, Berberine, Despiramine, 17-AAG, Curcumin, Calcitriol, Capsaicin, Camptothecin, Simvastatin, Salinomycin, (MBDAAGCCCSS) inhibits the expression of KAT6A and KAT6B, increases the expression of INK4a/ARF and other genes, promotes senescence, prevents cancer recurrence, and prolongs survival, via up-regulation of its target gene, 22/August/2018, 7.35  am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Medicinal Chemistry Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; The Walter and Eliza Hall Institute of Medical Research,…

read more

Combinatorial therapy for Metastatic ovarian cancers: A therapeutic mix encompassing  Metformin, 17-AAG, Carboplatin, Despiramine, Simvastatin, and Salinomycin (MAAGCDSS) inhibits the expression of FABP4, increases the expression of a number of tumor suppressor genes, and stifles the metastatic potential and the progression of ovarian cancers, via up-regulation of its target gene, 22/August/2017, 7.21 am
Combinatorial therapy for Metastatic ovarian cancers: A therapeutic mix encompassing  Metformin, 17-AAG, Carboplatin, Despiramine, Simvastatin, and Salinomycin (MAAGCDSS) inhibits the expression of FABP4, increases the expression of a number of tumor suppressor genes, and stifles the metastatic potential and the progression of ovarian cancers, via up-regulation of its target gene, 22/August/2017, 7.21 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA shows that “FABP4…

read more

Molecular therapy for cardiomyocyte proliferation and heart regeneration: Nucleolin, a nucleolar protein, decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up regulation of its target gene, 22/August/2018, 7.07 am
Molecular therapy for cardiomyocyte proliferation and heart regeneration: Nucleolin, a nucleolar protein, decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up regulation of its target gene, 22/August/2018, 7.07 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

read more
Start Typing